Targeted Delivery Drugs
Targeted Delivery Drugs

Targeted Delivery Drugs Comprehensive Study by Application (Hospital, Clinic, Others), Technology (Nanoparticles, Polymers (Micelles, Dendrimers), Monoclonal Antibodies, Gold Nanoparticles-Based Drug Delivery and Imaging, Drug-Eluting Stents), Therapeutic Area (Pulmonary (Inhalers, Dry Powder Inhalers, Nebulizers), Ocular Drug Delivery, Ocular Nano-Based Drug Delivery Implants (Liposomes, Polymers)) Players and Region - Global Market Outlook to 2026

Targeted Delivery Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 233 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Targeted Delivery Drugs Market?

Targeted drug delivery methods are of particular interest because they allow for concentrated delivery of a drug compound to its intended target, improving effectiveness while reducing off-target effects. Targeted drug delivery is a method of administering a drug in such a way that the concentration of the drug in specific areas of the body is significantly higher than in other parts of the body. Drugs can be injected into the human body.

The market study is being classified, by Application (Hospital, Clinic and Others) and major geographies with country level break-up.

Adverum Biotechnologies (United States), Arrowhead Pharmaceuticals (United States), Bayer AG (Germany), Windtree Therapeutics (United States), Immunocore (United Kingdom), Mankind Pharma (India), F. Hoffmann-La Roche AG (Switzerland), Ra Pharma (United States), Keystone Nano (United States), Lipocine (United States) and MultiVir (United States) are some of the key players profiled in the study.

The nature of the vendor landscape is immensely competitive with multinational companies establishing a stronghold over the rest. The players are focused on devising successful strategies, such as competent marketing, expansion of geographical reach, prudent pricing, high investment in R&D, and offering clinical laboratory services. Product innovation is also viewed as one of the major growth strategies adopted by companies to gain a stronger foothold in the market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Targeted Delivery Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Targeted Delivery Drugs market by Type, Application and Region.

On the basis of geography, the market of Targeted Delivery Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increase in Technological Advancement
  • Rise in the Use of Nanotechnology to Target a Specific Location
  • Reduce Waiting Time for an Improved Result

Market Trend
  • Increase in Research and Development to Enhance Product Portfolio

Restraints
  • High Cost for Treatment
  • Rise in Drug Re-calls

Opportunities
  • Growth Opportunities in Emerging Economies
  • Rising Innovation in Drug Discovery

Challenges
  • Streight Government Rules and Regulation


Market Leaders and some development strategies


“According to Pharmaceutical Regulatory Affairs, its act as an important role for approval of generics and the process is also being very stringent in various countries such as United States, Europe, Canada, Australia, and Japan includes standard skin irritation, sensitization and adhesion studies with the patch itself in animals/humans. The production of transdermal drug delivery system medications has increased, because these sorts of systems have proved more effective in many situations at directly sending drugs into the body.”

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Targeted Delivery Drugs Developer, Raw Material Suppliers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospital
  • Clinic
  • Others
By Technology
  • Nanoparticles
  • Polymers (Micelles, Dendrimers)
  • Monoclonal Antibodies
  • Gold Nanoparticles-Based Drug Delivery and Imaging
  • Drug-Eluting Stents

By Therapeutic Area
  • Pulmonary (Inhalers, Dry Powder Inhalers, Nebulizers)
  • Ocular Drug Delivery
  • Ocular Nano-Based Drug Delivery Implants (Liposomes, Polymers)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Technological Advancement
      • 3.2.2. Rise in the Use of Nanotechnology to Target a Specific Location
      • 3.2.3. Reduce Waiting Time for an Improved Result
    • 3.3. Market Challenges
      • 3.3.1. Streight Government Rules and Regulation
    • 3.4. Market Trends
      • 3.4.1. Increase in Research and Development to Enhance Product Portfolio
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Targeted Delivery Drugs, by Application, Technology, Therapeutic Area and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Targeted Delivery Drugs (Value)
      • 5.2.1. Global Targeted Delivery Drugs by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Clinic
        • 5.2.1.3. Others
      • 5.2.2. Global Targeted Delivery Drugs by: Technology (Value)
        • 5.2.2.1. Nanoparticles
        • 5.2.2.2. Polymers (Micelles, Dendrimers)
        • 5.2.2.3. Monoclonal Antibodies
        • 5.2.2.4. Gold Nanoparticles-Based Drug Delivery and Imaging
        • 5.2.2.5. Drug-Eluting Stents
      • 5.2.3. Global Targeted Delivery Drugs by: Therapeutic Area (Value)
        • 5.2.3.1. Pulmonary (Inhalers, Dry Powder Inhalers, Nebulizers)
        • 5.2.3.2. Ocular Drug Delivery
        • 5.2.3.3. Ocular Nano-Based Drug Delivery Implants (Liposomes, Polymers)
      • 5.2.4. Global Targeted Delivery Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Targeted Delivery Drugs (Price)
  • 6. Targeted Delivery Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Adverum Biotechnologies (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Arrowhead Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Windtree Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Immunocore (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mankind Pharma (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ra Pharma (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Keystone Nano (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lipocine (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. MultiVir (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Targeted Delivery Drugs Sale, by Application, Technology, Therapeutic Area and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Targeted Delivery Drugs (Value)
      • 7.2.1. Global Targeted Delivery Drugs by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Clinic
        • 7.2.1.3. Others
      • 7.2.2. Global Targeted Delivery Drugs by: Technology (Value)
        • 7.2.2.1. Nanoparticles
        • 7.2.2.2. Polymers (Micelles, Dendrimers)
        • 7.2.2.3. Monoclonal Antibodies
        • 7.2.2.4. Gold Nanoparticles-Based Drug Delivery and Imaging
        • 7.2.2.5. Drug-Eluting Stents
      • 7.2.3. Global Targeted Delivery Drugs by: Therapeutic Area (Value)
        • 7.2.3.1. Pulmonary (Inhalers, Dry Powder Inhalers, Nebulizers)
        • 7.2.3.2. Ocular Drug Delivery
        • 7.2.3.3. Ocular Nano-Based Drug Delivery Implants (Liposomes, Polymers)
      • 7.2.4. Global Targeted Delivery Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Targeted Delivery Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Targeted Delivery Drugs: by Application(USD Million)
  • Table 2. Targeted Delivery Drugs Hospital , by Region USD Million (2015-2020)
  • Table 3. Targeted Delivery Drugs Clinic , by Region USD Million (2015-2020)
  • Table 4. Targeted Delivery Drugs Others , by Region USD Million (2015-2020)
  • Table 5. Targeted Delivery Drugs: by Technology(USD Million)
  • Table 6. Targeted Delivery Drugs Nanoparticles , by Region USD Million (2015-2020)
  • Table 7. Targeted Delivery Drugs Polymers (Micelles, Dendrimers) , by Region USD Million (2015-2020)
  • Table 8. Targeted Delivery Drugs Monoclonal Antibodies , by Region USD Million (2015-2020)
  • Table 9. Targeted Delivery Drugs Gold Nanoparticles-Based Drug Delivery and Imaging , by Region USD Million (2015-2020)
  • Table 10. Targeted Delivery Drugs Drug-Eluting Stents , by Region USD Million (2015-2020)
  • Table 11. Targeted Delivery Drugs: by Therapeutic Area(USD Million)
  • Table 12. Targeted Delivery Drugs Pulmonary (Inhalers, Dry Powder Inhalers, Nebulizers) , by Region USD Million (2015-2020)
  • Table 13. Targeted Delivery Drugs Ocular Drug Delivery , by Region USD Million (2015-2020)
  • Table 14. Targeted Delivery Drugs Ocular Nano-Based Drug Delivery Implants (Liposomes, Polymers) , by Region USD Million (2015-2020)
  • Table 15. South America Targeted Delivery Drugs, by Country USD Million (2015-2020)
  • Table 16. South America Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 17. South America Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 18. South America Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 19. Brazil Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 20. Brazil Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 21. Brazil Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 22. Argentina Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 23. Argentina Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 24. Argentina Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 25. Rest of South America Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 27. Rest of South America Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 28. Asia Pacific Targeted Delivery Drugs, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 31. Asia Pacific Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 32. China Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 33. China Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 34. China Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 35. Japan Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 36. Japan Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 37. Japan Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 38. India Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 39. India Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 40. India Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 41. South Korea Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 42. South Korea Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 43. South Korea Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 44. Taiwan Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 45. Taiwan Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 46. Taiwan Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 47. Australia Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 48. Australia Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 49. Australia Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 53. Europe Targeted Delivery Drugs, by Country USD Million (2015-2020)
  • Table 54. Europe Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 55. Europe Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 56. Europe Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 57. Germany Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 58. Germany Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 59. Germany Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 60. France Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 61. France Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 62. France Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 63. Italy Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 64. Italy Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 65. Italy Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 66. United Kingdom Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 68. United Kingdom Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 69. Netherlands Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 70. Netherlands Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 71. Netherlands Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 72. Rest of Europe Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 74. Rest of Europe Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 75. MEA Targeted Delivery Drugs, by Country USD Million (2015-2020)
  • Table 76. MEA Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 77. MEA Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 78. MEA Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 79. Middle East Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 80. Middle East Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 81. Middle East Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 82. Africa Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 83. Africa Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 84. Africa Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 85. North America Targeted Delivery Drugs, by Country USD Million (2015-2020)
  • Table 86. North America Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 87. North America Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 88. North America Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 89. United States Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 90. United States Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 91. United States Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 92. Canada Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 93. Canada Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 94. Canada Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 95. Mexico Targeted Delivery Drugs, by Application USD Million (2015-2020)
  • Table 96. Mexico Targeted Delivery Drugs, by Technology USD Million (2015-2020)
  • Table 97. Mexico Targeted Delivery Drugs, by Therapeutic Area USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Targeted Delivery Drugs: by Application(USD Million)
  • Table 110. Targeted Delivery Drugs Hospital , by Region USD Million (2021-2026)
  • Table 111. Targeted Delivery Drugs Clinic , by Region USD Million (2021-2026)
  • Table 112. Targeted Delivery Drugs Others , by Region USD Million (2021-2026)
  • Table 113. Targeted Delivery Drugs: by Technology(USD Million)
  • Table 114. Targeted Delivery Drugs Nanoparticles , by Region USD Million (2021-2026)
  • Table 115. Targeted Delivery Drugs Polymers (Micelles, Dendrimers) , by Region USD Million (2021-2026)
  • Table 116. Targeted Delivery Drugs Monoclonal Antibodies , by Region USD Million (2021-2026)
  • Table 117. Targeted Delivery Drugs Gold Nanoparticles-Based Drug Delivery and Imaging , by Region USD Million (2021-2026)
  • Table 118. Targeted Delivery Drugs Drug-Eluting Stents , by Region USD Million (2021-2026)
  • Table 119. Targeted Delivery Drugs: by Therapeutic Area(USD Million)
  • Table 120. Targeted Delivery Drugs Pulmonary (Inhalers, Dry Powder Inhalers, Nebulizers) , by Region USD Million (2021-2026)
  • Table 121. Targeted Delivery Drugs Ocular Drug Delivery , by Region USD Million (2021-2026)
  • Table 122. Targeted Delivery Drugs Ocular Nano-Based Drug Delivery Implants (Liposomes, Polymers) , by Region USD Million (2021-2026)
  • Table 123. South America Targeted Delivery Drugs, by Country USD Million (2021-2026)
  • Table 124. South America Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 125. South America Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 126. South America Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 127. Brazil Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 128. Brazil Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 129. Brazil Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 130. Argentina Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 131. Argentina Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 132. Argentina Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 133. Rest of South America Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 134. Rest of South America Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 135. Rest of South America Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 136. Asia Pacific Targeted Delivery Drugs, by Country USD Million (2021-2026)
  • Table 137. Asia Pacific Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 138. Asia Pacific Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 139. Asia Pacific Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 140. China Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 141. China Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 142. China Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 143. Japan Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 144. Japan Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 145. Japan Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 146. India Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 147. India Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 148. India Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 149. South Korea Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 150. South Korea Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 151. South Korea Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 152. Taiwan Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 153. Taiwan Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 154. Taiwan Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 155. Australia Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 156. Australia Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 157. Australia Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 161. Europe Targeted Delivery Drugs, by Country USD Million (2021-2026)
  • Table 162. Europe Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 163. Europe Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 164. Europe Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 165. Germany Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 166. Germany Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 167. Germany Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 168. France Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 169. France Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 170. France Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 171. Italy Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 172. Italy Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 173. Italy Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 174. United Kingdom Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 175. United Kingdom Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 176. United Kingdom Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 177. Netherlands Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 178. Netherlands Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 179. Netherlands Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 180. Rest of Europe Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 181. Rest of Europe Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 182. Rest of Europe Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 183. MEA Targeted Delivery Drugs, by Country USD Million (2021-2026)
  • Table 184. MEA Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 185. MEA Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 186. MEA Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 187. Middle East Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 188. Middle East Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 189. Middle East Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 190. Africa Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 191. Africa Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 192. Africa Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 193. North America Targeted Delivery Drugs, by Country USD Million (2021-2026)
  • Table 194. North America Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 195. North America Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 196. North America Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 197. United States Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 198. United States Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 199. United States Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 200. Canada Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 201. Canada Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 202. Canada Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 203. Mexico Targeted Delivery Drugs, by Application USD Million (2021-2026)
  • Table 204. Mexico Targeted Delivery Drugs, by Technology USD Million (2021-2026)
  • Table 205. Mexico Targeted Delivery Drugs, by Therapeutic Area USD Million (2021-2026)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Targeted Delivery Drugs: by Application USD Million (2015-2020)
  • Figure 5. Global Targeted Delivery Drugs: by Technology USD Million (2015-2020)
  • Figure 6. Global Targeted Delivery Drugs: by Therapeutic Area USD Million (2015-2020)
  • Figure 7. South America Targeted Delivery Drugs Share (%), by Country
  • Figure 8. Asia Pacific Targeted Delivery Drugs Share (%), by Country
  • Figure 9. Europe Targeted Delivery Drugs Share (%), by Country
  • Figure 10. MEA Targeted Delivery Drugs Share (%), by Country
  • Figure 11. North America Targeted Delivery Drugs Share (%), by Country
  • Figure 12. Global Targeted Delivery Drugs share by Players 2020 (%)
  • Figure 13. Global Targeted Delivery Drugs share by Players (Top 3) 2020(%)
  • Figure 14. Global Targeted Delivery Drugs share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Adverum Biotechnologies (United States) Revenue, Net Income and Gross profit
  • Figure 17. Adverum Biotechnologies (United States) Revenue: by Geography 2020
  • Figure 18. Arrowhead Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 19. Arrowhead Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 20. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 22. Windtree Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Windtree Therapeutics (United States) Revenue: by Geography 2020
  • Figure 24. Immunocore (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Immunocore (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Mankind Pharma (India) Revenue, Net Income and Gross profit
  • Figure 27. Mankind Pharma (India) Revenue: by Geography 2020
  • Figure 28. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Ra Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 31. Ra Pharma (United States) Revenue: by Geography 2020
  • Figure 32. Keystone Nano (United States) Revenue, Net Income and Gross profit
  • Figure 33. Keystone Nano (United States) Revenue: by Geography 2020
  • Figure 34. Lipocine (United States) Revenue, Net Income and Gross profit
  • Figure 35. Lipocine (United States) Revenue: by Geography 2020
  • Figure 36. MultiVir (United States) Revenue, Net Income and Gross profit
  • Figure 37. MultiVir (United States) Revenue: by Geography 2020
  • Figure 38. Global Targeted Delivery Drugs: by Application USD Million (2021-2026)
  • Figure 39. Global Targeted Delivery Drugs: by Technology USD Million (2021-2026)
  • Figure 40. Global Targeted Delivery Drugs: by Therapeutic Area USD Million (2021-2026)
  • Figure 41. South America Targeted Delivery Drugs Share (%), by Country
  • Figure 42. Asia Pacific Targeted Delivery Drugs Share (%), by Country
  • Figure 43. Europe Targeted Delivery Drugs Share (%), by Country
  • Figure 44. MEA Targeted Delivery Drugs Share (%), by Country
  • Figure 45. North America Targeted Delivery Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Adverum Biotechnologies (United States)
  • Arrowhead Pharmaceuticals (United States)
  • Bayer AG (Germany)
  • Windtree Therapeutics (United States)
  • Immunocore (United Kingdom)
  • Mankind Pharma (India)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Ra Pharma (United States)
  • Keystone Nano (United States)
  • Lipocine (United States)
  • MultiVir (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation